首页|治疗幽门螺杆菌感染的研究进展

治疗幽门螺杆菌感染的研究进展

扫码查看
幽门螺杆菌(Helicobacter pylori,Hp)作为一种常见致病菌,感染了全球半数以上人口,与胃炎、消化性溃疡和胃癌等多种疾病密切相关。随着Hp耐药问题的日益严重,传统抗菌药物联合疗法面临着根除率不断下降的巨大风险,优化现有治疗方案并发展新的根除策略成为亟待解决的问题。当前,抗Hp治疗的研究已经拓展至功能性益生菌、纳米药物、光疗、中西医结合和抗菌肽等领域。本文旨在概述近年来新发展的抗Hp治疗方法,并为Hp根除的替代治疗提供见解。
Research progress in the treatment of Helicobacter pylori infection
Helicobacter pylori(H.pylori),as a common pathogenic bacterium,has infected more than half of the world's population,and is closely related to many diseases such as gastritis,peptic ulcer disease and gastric cancer.With the increasing problem of H.pylori's drug resistance,traditional antimicrobial drug combi-nation therapies face a great risk of declining eradication rate.Therefore,it is urgent to optimize the existing treatment options and find new eradication strategies.Presently,the research on the treatment of H.pylori infection has been extended to functional probiotics,nanomedicine,phototherapy,integrated traditional Chi-nese and western medicine,and antimicrobial peptide.The purpose of this paper was to provide an overview of the newly developed anti-H.pylori therapies in recent years and provide insights into alternative treatments for H.pylori eradication.

Helicobacter pyloridrug resistanceprobioticsnanomedicinephototherapyintegrated Chinese and western medicineantimicrobial peptide

林洋、杨慧、李君翔、张湘云、张春江

展开 >

兰州大学生命科学学院,甘肃 兰州 730000

兰州大学细胞活动与逆境适应教育部重点实验室,甘肃 兰州 730000

兰州大学药学院,甘肃 兰州 730000

幽门螺杆菌 药物耐药 益生菌 纳米药物 光疗 中西医结合 抗菌肽

甘肃省重点人才资助项目广州市科技计划资助项目

2022RCXM027202206010165

2024

兰州大学学报(医学版)
兰州大学

兰州大学学报(医学版)

CSTPCD
影响因子:0.641
ISSN:1000-2812
年,卷(期):2024.50(9)